The Company entered into a License Agreement with Novartis granting global ... subsequently launch a basket of products in the cardiovascular, central nervous system and oral anti-diabetes area.

Fintel reports that on November 12, 2024, Wolfe Research downgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) ...

AGTC’s development foci are centred on rare ophthalmic, otologic, and central nervous system (CNS ... of certain milestones related to AGTC’s products. Chief investment officer of Syncona ...

ABL has data showing that ABL301 can penetrate the central nervous system and, once there ... At the end of 2021, for example, Novartis paid $150 million upfront for rights to an orally-active ...

Acadia Pharmaceuticals ACAD reported third-quarter 2024 earnings of 20 cents per share, beating the Zacks Consensus Estimate ...

VIVOLTA, the medical electrospinning solutions provider, has partnered with Neurochase, to make micro-catheters to deliver therapies to the brain.

Antibody MarketThe global antibody market is projected to experience substantial growth, with an estimated market size of USD ...

Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.

The Global Topical Drug Delivery Market Size is projected to grow at a CAGR of 6.3% from 2024 to 2031, according to a new report published by Verified Market Research ®. The report reveals that the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma ...